Supplementary Table S1 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer

Supplementary Table S1 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer

<p>Summarized metrics for WES data</p>

Збережено в:

Бібліографічні деталі
Автор:	Emil Christensen (15054394) (author)
Інші автори:	Iver Nordentoft (15054397) (author), Karin Birkenkamp-Demtröder (15054400) (author), Sara K. Elbæk (15054403) (author), Sia V. Lindskrog (15054406) (author), Ann Taber (15054409) (author), Tine G. Andreasen (15054412) (author), Trine Strandgaard (15054415) (author), Michael Knudsen (15054418) (author), Philippe Lamy (15054421) (author), Mads Agerbæk (15054424) (author), Jørgen B. Jensen (15054427) (author), Lars Dyrskjøt (15054430) (author)
Опубліковано:	2025
Предмети:	Cancer Cancer Detection and Diagnosis Therapeutic Research and Development Methods and Technology Biomarkers Prognostic biomarkers Genitourinary Cancers Bladder cancer Liquid Biopsy Translational Research
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси

Supplementary Table S2 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
за авторством: Emil Christensen (15054394)
Опубліковано: (2025)

Table S1-S8 from Urinary Tumor DNA MRD Analysis to Identify Responders to Neoadjuvant Immunotherapy in Muscle-invasive Bladder Cancer
за авторством: Ruiyun Zhang (17142498)
Опубліковано: (2025)

Supplementary Figures S1-S4 from Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial
за авторством: Giuseppe Basile (15051269)
Опубліковано: (2025)

Supplementary Tables S1-S15 from Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells
за авторством: Iris van 't Erve (15054503)
Опубліковано: (2025)

TS1-9 from Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer
за авторством: Lavanya Sivapalan (15314248)
Опубліковано: (2025)

Supplementary Figure S1 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
за авторством: Kala Visvanathan (14952973)
Опубліковано: (2025)

Supplementary Figure S2 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
за авторством: Kala Visvanathan (14952973)
Опубліковано: (2025)

Supplementary Figure S3 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
за авторством: Kala Visvanathan (14952973)
Опубліковано: (2025)

Supplementary Figure S4 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
за авторством: Kala Visvanathan (14952973)
Опубліковано: (2025)

Supplementary Figure S5 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
за авторством: Kala Visvanathan (14952973)
Опубліковано: (2025)

Supplementary Data 2 from Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study
за авторством: Ismael Fernández-Miranda (15051932)
Опубліковано: (2025)

Supplementary Data S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
за авторством: Andrew A. Davis (15030032)
Опубліковано: (2025)

Supplementary Data 1 from Early Changes in Circulating Cell-Free <i>KRAS</i> G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients
за авторством: Cloud P. Paweletz (14960112)
Опубліковано: (2025)

Figure 1 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
за авторством: James R. Larkin (14936324)
Опубліковано: (2025)

Figure 2 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
за авторством: James R. Larkin (14936324)
Опубліковано: (2025)

Figure 3 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
за авторством: James R. Larkin (14936324)
Опубліковано: (2025)

Figure 4 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
за авторством: James R. Larkin (14936324)
Опубліковано: (2025)

Figure 5 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
за авторством: James R. Larkin (14936324)
Опубліковано: (2025)

Table 1 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
за авторством: James R. Larkin (14936324)
Опубліковано: (2025)

Supplemental Table 1 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
за авторством: Morten Lapin (15056728)
Опубліковано: (2025)

Supplemental Table 2 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
за авторством: Morten Lapin (15056728)
Опубліковано: (2025)

Supplemental Table 3 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
за авторством: Morten Lapin (15056728)
Опубліковано: (2025)

Table S1 from Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection
за авторством: Nina Rao (15321199)
Опубліковано: (2025)

Table S2 from Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection
за авторством: Nina Rao (15321199)
Опубліковано: (2025)

Table S3 from Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection
за авторством: Nina Rao (15321199)
Опубліковано: (2025)

Table S4 from Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection
за авторством: Nina Rao (15321199)
Опубліковано: (2025)

Table S5 from Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection
за авторством: Nina Rao (15321199)
Опубліковано: (2025)

Table S6 from Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection
за авторством: Nina Rao (15321199)
Опубліковано: (2025)

Table S7 from Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection
за авторством: Nina Rao (15321199)
Опубліковано: (2025)

Supplementary Table S1 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
за авторством: Sofie H. Tolmeijer (15313251)
Опубліковано: (2025)

Supplementary Table S2 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
за авторством: Sofie H. Tolmeijer (15313251)
Опубліковано: (2025)

Supplementary Table S3 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
за авторством: Sofie H. Tolmeijer (15313251)
Опубліковано: (2025)

Supplementary Table S4 from Blood-Based Diagnosis and Risk Stratification of Patients with Pancreatic Intraductal Papillary Mucinous Neoplasm (IPMN)
за авторством: Chaoyang Zhang (15051876)
Опубліковано: (2025)

Supplementary Table S6 from Blood-Based Diagnosis and Risk Stratification of Patients with Pancreatic Intraductal Papillary Mucinous Neoplasm (IPMN)
за авторством: Chaoyang Zhang (15051876)
Опубліковано: (2025)

Supplementary Data 1 from Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis
за авторством: Nam Q. Bui (14958210)
Опубліковано: (2025)

Supplementary Data 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
за авторством: Francesca Orzan (15055579)
Опубліковано: (2025)

Supplementary Data 2 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
за авторством: Francesca Orzan (15055579)
Опубліковано: (2025)

Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
за авторством: Francesca Orzan (15055579)
Опубліковано: (2025)

Supplementary Video S1 from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
за авторством: Xiaojiang Duan (15439264)
Опубліковано: (2025)

Supplementary Video S2A from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
за авторством: Xiaojiang Duan (15439264)
Опубліковано: (2025)

Cannot write session to /tmp/vufind_sessions/sess_pbhsalvlc8t0mqauhmoupbsbfp